查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1782020

液體活體組織切片市場，按樣本類型、按生物標記、按技術、按產品、按臨床應用、按應用、按最終用戶、按國家/地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率及預測

Liquid Biopsy Market, By Sample Type, By Biomarker, By Technology, By Product, By Clinical Application, By Application, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 383 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年液體切片市場規模價值 121.2424 億美元，2025 年至 2032 年的複合年成長率為 11.6%。

液體切片市場-市場動態

預計癌症盛行率的上升將推動早期篩檢和治療的需求，從而推動市場成長。

隨著癌症成為全球發病率和死亡率的主要原因，醫療保健系統越來越重視早期診斷，以便在惡性腫瘤發展之前發現它們。這種轉變推動了先進篩檢技術的使用，包括液體活體組織切片、影像技術和分子診斷評估。美國國家癌症研究所預測，到2025年，美國將新增約2,041,910例癌症病例，其中618,120例死於癌症。因此，涵蓋早期診斷到治療的癌症護理全過程正在快速發展，以滿足日益成長的醫療保健需求，從而進一步刺激早期篩檢工具和突破性療法的市場發展。此外，基因組學和分子技術的進步可能為市場帶來成長機會。然而，缺乏標準化和監管障礙可能會阻礙市場擴張。

液體活體組織切片市場－關鍵見解

根據我們的研究分析師的分析，預計全球市場在預測期內（2025-2032 年）的年複合成長率約為 11.6%。

根據樣本類型細分，預計血液樣本將在 2024 年佔據最大市場佔有率

根據生物標記細分，循環腫瘤細胞 (CTC) 是 2024 年的主要應用

根據技術細分，多基因平行分析 (NGS) 是 2024 年的領先技術

根據產品細分，儀器是 2024 年的主導產品

根據臨床應用細分，治療選擇是 2024 年領先的最終用戶

根據應用程式細分，癌症是 2024 年領先的最終用戶

根據最終用戶細分，醫院和實驗室是 2024 年的主要最終用戶

從地區來看，北美是 2024 年最大的收入來源

液體活體組織切片市場-細分分析：

全球液體活體組織切片市場根據樣本類型、應用、技術、產品、臨床應用、應用、最終用戶和地區進行細分。

根據樣本類型，市場分為三個部分：血液樣本和其他樣本。血液樣本是市場成長的主要驅動力。血液樣本在液體活體組織切片領域佔據主導地位，主要是因為其易於採集、侵入性低且患者依從性高。以血液為基礎的液體活體組織切片有助於檢測和分析循環腫瘤DNA (ctDNA)、循環腫瘤細胞 (CTC) 和其他各種生物標記物，從而即時全面地概述腫瘤的基因圖譜。與組織切片相比，血液樣本為癌症診斷、預後、治療監測和早期檢測提供了更快速、更安全、更經濟的選擇。醫院、診斷中心和研究機構廣泛採用以血液為基礎的檢測，進一步鞏固了其在市場上的領先地位。

根據生物標記，市場可分為三個細分領域：循環腫瘤細胞 (CTC)、循環腫瘤DNA (ctDNA) 和細胞外載體 (EV) 等。循環腫瘤細胞 (CTC) 引領著市場的成長。 CTC 是液體活體組織切片市場成長的主要驅動力，因為它們在癌症診斷、預後和治療監測中發揮重要作用。 CTC 是從原發性或轉移性腫瘤中分離出來並在血液中傳播的癌細胞，為了解腫瘤異質性和轉移潛能提供了重要資訊。 CTC 無需侵入性操作即可提供疾病進展和治療反應的即時資料，使其成為腫瘤學中首選的生物標記。

根據技術，市場可分為兩大細分領域：多基因平行分析 (NGS) 和單基因分析（PCR 微陣列）。多基因平行分析 (NGS) 是市場成長的主要驅動力。利用新一代定序 (NGS) 進行的多基因平行分析，能夠同時評估多種基因變異，並具有卓越的靈敏度和特異性，從而推動了液體活體組織切片市場的成長。 NGS 能夠從小樣本量中進行廣泛的基因組分析，使臨床醫生能夠深入了解腫瘤生物學、突變負荷和可能的治療標靶。該方法尤其有利於個人化醫療，因為它能夠即時識別罕見突變和抗藥性機制。基於 NGS 的液體活體組織切片組合在腫瘤學中的應用日益廣泛，用於早期癌症檢測、治療選擇和微小殘留疾病的監測，這極大地促進了市場的成長。

市場依產品細分為三類：儀器、耗材、試劑盒及試劑，以及軟體及服務。儀器引領著市場的成長。儀器處於液體活體組織切片市場擴張的前沿，這得益於對能夠準確識別和分析循環生物標記（例如循環腫瘤細胞 (CTC)、循環腫瘤 DNA (ctDNA) 和外泌體）的尖端技術日益成長的需求。這些儀器包括 NGS 平台、PCR 系統、微流體設備和自動化液體處理系統，對於實現診斷過程的高通量、靈敏度和精確度至關重要。專為腫瘤學應用而設計的創新、方便用戶使用和整合系統的不斷發展，加速了其在醫院、診斷實驗室和研究機構中的應用。

根據臨床應用，市場可分為四個細分領域：療法選擇、治療監測、早期癌症篩檢、復發監測等。療法選擇是市場成長的主要驅動力。透過檢測循環腫瘤DNA (ctDNA) 或其他生物標記物，液體活體組織切片無需進行侵入性組織取樣即可檢測特定突變、基因融合和抗藥性機制。這種方法使腫瘤學家能夠根據患者獨特的分子特徵量身定做治療方案，例如標靶治療或免疫治療，從而改善臨床療效並減少不必要的毒性。精準醫療日益受到關注，加上液體活體組織切片能夠追蹤治療過程中腫瘤的動態變化，進一步強化了其在不同癌症類型療法選擇中的重要作用。

根據應用，市場可分為八個部分：癌症、生殖健康、肺癌、攝護腺癌、乳癌、大腸癌、白血病、胃腸道癌症和其他。癌症部分處於市場成長的前沿。在液體活體組織切片領域，癌症部分正在推動市場擴張，這得益於全球各種癌症患病率的上升以及對非侵入性診斷方法的需求不斷成長。液體活體組織切片透過檢查來自體液（主要是血液）的生物標記（例如 ctDNA、CTC 和外泌體），為癌症的早期發現、腫瘤分析、治療監測和預測復發提供了一種革命性的方法。與傳統組織活體組織切片相比，它具有降低風險、縮短週轉時間以及捕捉腫瘤異質性的能力等優勢，使其成為腫瘤學的重要工具。隨著精準醫療在癌症治療中變得越來越重要，液體活體組織切片在肺癌、乳腺癌、大腸直腸癌和前列腺癌等實體腫瘤管理中的應用不斷成長，進一步推動了這一領域的發展。

根據最終用戶，市場可分為四個細分市場：醫院和實驗室、專科診所、學術和研究中心以及其他。醫院和實驗室細分市場處於市場成長的前沿。由於先進診斷技術的普及以及在這些環境中進行的癌症篩檢和監測程序的增多，該細分市場正在推動液體活體組織切片行業的擴張。醫院和臨床實驗室通常是接受診斷評估的患者最初的接觸點，因此它們成為部署液體活體組織切片測試的重要中心。這些機構的優勢在於擁有熟練的專業人員、完善的基礎設施以及可使用NGS和PCR平台等高通量儀器。

液體活體組織切片市場——地理洞察

北美市場成長領先，這歸功於其強大的研發實力和完善的報銷框架。該地區完善的醫療保健體系提高了人們對早期癌症篩檢的認知，學術機構與行業利益相關者之間強力的合作進一步鞏固了北美在全球液體活體組織切片市場的突出地位。根據美國醫學會 (American Medical Association) 報道，美國在 2023 年的醫療保健撥款為 4.8665 兆美元。由於癌症認知度的提高、醫療保健可近性的提升以及政府對早期檢測計劃的資助，歐洲也佔據了相當大的市場佔有率。

液體切片市場-競爭格局：

液體切片市場競爭激烈，不斷發展變化，許多老牌企業和新進者都力求透過創新、合作和成長策略來鞏固競爭優勢。各家公司正利用諸如新一代定序 (NGS)、液滴式數位 PCR 和多基因面板檢測等尖端技術展開競爭，以提高液體活體組織切片檢測的靈敏度、特異性和速度。領先的公司正更加重視亞太和拉丁美洲的新興市場，透過設立區域子公司和分銷網路來抓住尚未開發的機會。

最新動態：

2023年11月1日，全球DNA定序與晶片技術領導企業Illumina公司宣布推出新一代分散式液體切片檢測系統，用於基因組分析。最新的TruSight Oncology 500 ctDNA v2（TSO 500 ctDNA v2）是一款研究型檢測系統，可在無法進行組織檢測的情況下，對從血液樣本中提取的循環腫瘤DNA (ctDNA) 進行非侵入性全面基因組分析 (CGP)，或增強基於組織的檢測。

目錄

第1章：液體活體組織切片市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 液體活體組織切片市場按樣本類型分類
    • 液體活體組織切片市場片段（按生物標記）
    • 液體切片市場技術片段
    • 液體切片市場產品片段
    • 液體活體組織切片市場片段（按臨床應用）
    • 液體活體組織切片市場片段（按應用）
    • 液體活體組織切片市場片段（按最終用戶）
    • 液體活體組織切片市場（按國家/地區）
    • 液體活體組織切片市場（按地區）
  • 競爭洞察

第3章：液體切片檢查主要市場趨勢

  • 液體活體組織切片市場促進因素
    • 市場促進因素的影響分析
  • 液體切片市場限制
    • 市場限制的影響分析
  • 液體切片市場機遇
  • 液體切片市場未來趨勢

第4章：液體活體組織切片產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：液體切片市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：液體切片市場格局

  • 2024年液體切片市場佔有率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：液體切片市場－依樣本類型

  • 概述
    • 依樣本類型進行細分佔有率分析
    • 血液樣本
    • 其他

第 8 章：液體活體組織切片市場 - 按生物標記

  • 概述
    • 按生物標記細分的市佔率分析
    • 循環腫瘤細胞（CTC）
    • 循環腫瘤DNA（ctDNA）
    • 細胞外載體（EV）
    • 其他

第9章：液體切片市場－依技術

  • 概述
    • 按技術細分的市場佔有率分析
    • 多基因平行分析（NGS）
    • 單基因分析（PCR微陣列）

第 10 章：液體活體組織切片市場 - 按產品

  • 概述
    • 按產品細分的市佔率分析
    • 儀器
    • 耗材套件和試劑
    • 軟體和服務

第 11 章：液體活體組織切片市場 - 按臨床應用

  • 概述
    • 按臨床應用分類的細分市場佔有率分析
    • 治療選擇
    • 治療監測
    • 早期癌症篩檢
    • 復發監測
    • 其他

第 12 章：液體活體組織切片市場 - 按應用

  • 概述
    • 按應用細分市場佔有率分析
    • 癌症
    • 生殖健康
    • 肺癌
    • 攝護腺癌
    • 乳癌
    • 大腸直腸癌
    • 白血病
    • 胃腸道癌症
    • 其他

第 13 章：液體活體組織切片市場 - 按最終用戶

  • 概述
    • 按最終用戶細分的佔有率分析
    • 醫院和實驗室
    • 專科診所
    • 學術和研究中心
    • 其他

第 14 章：液體活體組織切片市場-按地域分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美液體活體組織切片主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模和預測（按樣本類型）
    • 北美市場規模及預測（依生物標記）
    • 北美市場規模和預測（按技術）
    • 北美市場規模及預測（按產品）
    • 北美市場規模與預測，按臨床應用
    • 北美市場規模和預測（按應用）
    • 北美市場規模及預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲液體切片檢查主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（依樣本類型）
    • 歐洲市場規模及預測（依生物標記）
    • 歐洲市場規模與預測（按技術）
    • 歐洲市場規模及預測（按產品）
    • 歐洲市場規模與預測，按臨床應用
    • 歐洲市場規模和預測，按應用
    • 歐洲市場規模及預測（按最終用戶）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區液體活體組織切片主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依樣本類型）
    • 亞太地區生物標記市場規模及預測
    • 亞太地區市場規模及預測（依技術）
    • 亞太地區市場規模及預測（依產品）
    • 亞太地區市場規模及預測（依臨床應用）
    • 亞太地區市場規模及預測（按應用）
    • 亞太地區市場規模及預測（依最終用戶）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲液體活體組織切片主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（依樣本類型）
    • 拉丁美洲市場規模及預測（按生物標記）
    • 拉丁美洲市場規模及預測（按技術）
    • 拉丁美洲市場規模及預測（按產品）
    • LATAM 規模及預測（依臨床應用）
    • LATAM 規模和預測（按應用）
    • 拉丁美洲地區規模及預測（依最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲液體活體組織切片主要製造商
    • 中東和非洲市場規模及預測（按國家/地區）
    • 中東和非洲市場規模及預測（按樣本類型）
    • 中東和非洲市場規模及預測（按生物標記）
    • 中東和非洲市場規模及預測（按技術）
    • 中東和非洲市場規模及預測（按產品）
    • 中東及非洲市場規模及預測（依臨床應用）
    • 中東和非洲市場規模和預測（按應用）
    • 中東和非洲市場規模及預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 15 章：液體活體組織切片產業主要供應商分析

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • Guardant Health, Inc.
    • Foundation Medicine, Inc. (Roche subsidiary)
    • Illumina, Inc.
    • GRAIL, Inc. (subsidiary of Illumina)
    • Bio-Rad Laboratories, Inc.
    • Exact Sciences Corporation
    • Thermo Fisher Scientific Inc.
    • Natera, Inc.
    • Freenome Holdings, Inc.
    • QIAGEN NV
    • Lucence Diagnostics
    • Inivata Ltd. (NeoGenomics subsidiary)
    • Angle plc
    • Sysmex Corporation
    • Biocept, Inc.
    • Oncocyte Corporation
    • Personal Genome Diagnostics (PGDx)
    • Chronix Biomedical
    • Epic Sciences, Inc.
    • Cynvenio Biosystems, Inc.
    • Others

第 16 章：360 度分析師視角

第 17 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5421

REPORT HIGHLIGHT

Liquid Biopsy Market size was valued at US$ 12,124.24 Million in 2024, expanding at a CAGR of 11.6% from 2025 to 2032.

A liquid biopsy is a non-invasive diagnostic procedure that evaluates bodily fluids, mainly blood, to identify cancer or other illnesses. It analyzes biomarkers such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) to detect genetic or molecular alterations linked to a tumor. Liquid biopsies can facilitate early cancer detection, monitor the effectiveness of treatments, and evaluate tumor progression. Much of the initial research on liquid biopsies has focused on lung, breast, and prostate cancers; however, this technology is anticipated to influence all cancer types. Liquid biopsy represents a relatively recent testing method with numerous potential revolutionary applications in cancer therapy, including several uses that have received approval from the U.S. Food and Drug Administration (FDA). Ongoing research continues to explore its advantages.

Liquid Biopsy Market- Market Dynamics

The increasing prevalence of cancer is anticipated to boost the demand for early screening and therapeutics, thereby driving market growth.

As cancer emerges as a primary contributor to morbidity and mortality globally, healthcare systems are increasingly prioritizing early-stage diagnostics to detect malignancies before their advancement. This shift is propelling the utilization of sophisticated screening technologies, including liquid biopsies, imaging techniques, and molecular diagnostic assessments. The National Cancer Institute projects that by 2025, approximately 2,041,910 new cancer cases will be identified in the United States, with 618,120 fatalities attributed to the disease. Consequently, the cancer care continuum, encompassing early diagnosis through to treatment, is rapidly evolving to address the escalating healthcare demands, thereby further stimulating the market for both early screening instruments and groundbreaking therapeutics. Additionally, advancements in genomic and molecular technologies may present growth opportunities for the market. Nevertheless, the lack of standardization and regulatory hurdles could impede market expansion.

Liquid Biopsy Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.6% over the forecast period (2025-2032)

Based on the Sample Type segmentation, the Blood Sample was predicted to show maximum market share in the year 2024

Based on Biomarker segmentation, Circulating Tumor Cells (CTCs) were the leading application in 2024

Based on Technology segmentation, Multi-gene-parallel Analysis (NGS) was the leading Technology in 2024

Based on Product segmentation, Instruments were the leading Product in 2024

Based on Clinical application segmentation, Therapy Selection was the leading End-User in 2024

Based on Application segmentation, Cancer was the leading End-User in 2024

Based on End-User segmentation, Hospitals and Laboratories were the leading End-User in 2024

Based on region, North America was the leading revenue generator in 2024

Liquid Biopsy Market- Segmentation Analysis:

The Global Liquid Biopsy Market is segmented based on Sample Type, Application, Technology, Product, Clinical Application, Application, End-User, and Region.

The market is categorized into three segments according to Sample Type: Blood Sample and Others. Blood Sample is the primary driver of market growth. Blood samples dominate the Liquid Biopsy sector, mainly due to their ease of collection, low invasiveness, and high levels of patient compliance. Blood-based liquid biopsies facilitate the detection and analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and various other biomarkers, providing a thorough overview of the tumor's genetic profile in real-time. In comparison to tissue biopsies, blood samples offer a quicker, safer, and more economical option for cancer diagnosis, prognosis, treatment monitoring, and early detection. The extensive adoption of blood-based tests by hospitals, diagnostic centers, and research institutions further reinforces their leading position in the market.

The market is categorized into three segments based on biomarkers: Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), and Extracellular Vehicles (EVs), among others. Circulating Tumor Cells (CTCs) lead the growth of the market. CTCs are the primary drivers of growth in the Liquid Biopsy market, due to their significant role in cancer diagnosis, prognosis, and treatment monitoring. CTCs are cancer cells that separate from primary or metastatic tumors and travel through the bloodstream, providing essential insights into tumor heterogeneity and metastatic potential. Their capacity to deliver real-time data on disease progression and treatment response without requiring invasive procedures renders them a preferred biomarker in oncology.

The market is categorized into two segments based on technology: Multi-gene-parallel Analysis (NGS) and Single Gene Analysis (PCR Microarrays). Multi-gene-parallel Analysis (NGS) is the primary driver of market growth. The multi-gene parallel analysis utilising Next-Generation Sequencing (NGS) leads to the growth of the Liquid Biopsy market, owing to its capability to concurrently assess multiple genetic alterations with exceptional sensitivity and specificity. NGS facilitates extensive genomic profiling from small sample volumes, equipping clinicians with in-depth insights into tumor biology, mutation load, and possible therapeutic targets. This methodology is particularly beneficial for personalized medicine, as it enables the identification of rare mutations and resistance mechanisms in real time. The rising implementation of NGS-based liquid biopsy panels in oncology for early cancer detection, treatment selection, and monitoring of minimal residual disease is greatly enhancing the market's growth.

The market is segmented into three categories based on Product: Instruments, Consumables Kits and Reagents, and Software and Services. Instruments lead the growth of the market. Instruments are at the forefront of the Liquid Biopsy market expansion, propelled by the rising demand for sophisticated technologies that can accurately identify and analyze circulating biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes. These instruments, which include NGS platforms, PCR systems, microfluidic devices, and automated liquid handling systems, are crucial for achieving high throughput, sensitivity, and precision in diagnostic processes. The ongoing advancement of innovative, user-friendly, and integrated systems designed for oncology applications has accelerated their adoption in hospitals, diagnostic laboratories, and research institutions.

The market is categorized into four segments based on Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, and Others. Therapy Selection is the primary driver of market growth. By examining circulating tumor DNA (ctDNA) or other biomarkers, liquid biopsy facilitates the detection of specific mutations, gene fusions, and resistance mechanisms without requiring invasive tissue sampling. This method enables oncologists to customize therapies such as targeted treatments or immunotherapies according to a patient's distinct molecular profile, thereby enhancing clinical outcomes and reducing unnecessary toxicity. The increasing focus on precision medicine, coupled with the capability of liquid biopsy to track dynamic tumor alterations during treatment, further reinforces its essential role in therapy selection across different cancer types.

The market is categorized into eight segments based on application: Cancer, Reproductive Health, Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Gastrointestinal Cancer, and Others. The cancer segment is at the forefront of market growth. In the Liquid Biopsy sector, the cancer segment is driving market expansion, propelled by the increasing global prevalence of various cancers and the rising demand for non-invasive diagnostic methods. Liquid biopsy provides a revolutionary method for the early detection of cancer, tumor profiling, treatment monitoring, and predicting relapses by examining biomarkers such as ctDNA, CTCs, and exosomes derived from body fluids-mainly blood. Its benefits over conventional tissue biopsies, which include reduced risk, faster turnaround times, and the capacity to capture tumor heterogeneity, have established it as an essential instrument in oncology. As precision medicine becomes more integral to cancer treatment, the application of liquid biopsy in the management of solid tumors like lung, breast, colorectal, and prostate cancer is continually growing, further propelling the advancement of this segment.

The market is categorized into four segments based on End-User: Hospitals and Laboratories, Specialty Clinics, Academic and Research Centers, and Others. The Hospitals and Laboratories segment is at the forefront of market growth. This segment is driving the expansion of the Liquid Biopsy industry due to the increasing adoption of advanced diagnostic technologies and the growing number of cancer screening and monitoring procedures conducted in these environments. Hospitals and clinical laboratories frequently serve as the initial point of contact for patients undergoing diagnostic assessments, rendering them essential centers for the deployment of liquid biopsy tests. These institutions gain advantages from the presence of skilled professionals, established infrastructure, and access to high-throughput instruments such as NGS and PCR platforms.

Liquid Biopsy Market- Geographical Insights

North America leads in market growth, attributed to robust research and development as well as a solid reimbursement framework. The region's sophisticated healthcare system heightened awareness regarding early cancer screening, and strong partnerships between academic institutions and industry stakeholders further solidify North America's prominent role in the global liquid biopsy market. As reported by the American Medical Association, the United States allocated USD 4,866.5 billion for healthcare in 2023. Europe also orders a substantial portion of the market, bolstered by increasing cancer awareness, enhanced access to healthcare, and government funding for early detection initiatives.

Liquid Biopsy Market- Competitive Landscape:

The liquid biopsy market is characterized by intense competition and constant evolution, with numerous established and new entrants seeking to secure a competitive advantage through innovation, collaborations, and growth strategies. Firms are competing based on cutting-edge technologies such as next-generation sequencing (NGS), droplet digital PCR, and multi-gene panel testing to enhance the sensitivity, specificity, and speed of liquid biopsy assays. Leading companies are placing greater emphasis on emerging markets in the Asia Pacific and Latin America by setting up regional subsidiaries and distribution networks to seize untapped opportunities.

Recent Developments:

On November 1, 2023, Illumina Inc., a worldwide frontrunner in DNA sequencing and array-based technologies, announced the launch of a new generation of its distributed liquid biopsy assay designed for genomic profiling. The latest TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that facilitates noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) extracted from blood samples when tissue testing is not feasible, or enhances tissue-based testing.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LIQUID BIOPSY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Guardant Health, Inc.
  • Foundation Medicine, Inc. (Roche subsidiary)
  • Illumina, Inc.
  • GRAIL, Inc. (a subsidiary of Illumina)
  • Bio-Rad Laboratories, Inc.
  • Exact Sciences Corporation
  • Thermo Fisher Scientific Inc.
  • Natera, Inc.
  • Freenome Holdings, Inc.
  • QIAGEN N.V.
  • Lucence Diagnostics
  • Inivata Ltd. (NeoGenomics subsidiary)
  • Angle plc
  • Sysmex Corporation
  • Biocept, Inc.
  • Oncocyte Corporation
  • Personal Genome Diagnostics (PGDx)
  • Chronix Biomedical
  • Epic Sciences, Inc.
  • Cynvenio Biosystems, Inc.
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY SAMPLE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Blood Sample
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER- MARKET ANALYSIS, 2019 - 2032

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (ctDNA)
  • Extracellular Vehicles (EVs)
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

  • Multi-gene-parallel Analysis (NGS)
  • Single Gene Analysis (PCR Microarrays)

GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032

  • Instruments
  • Consumables Kits and Reagents
  • Software and Services

GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Therapy Selection
  • Treatment Monitoring
  • Early Cancer Screening
  • Recurrence Monitoring
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Cancer
  • Reproductive Health
  • Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Gastrointestinal Cancer
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals and Laboratories
  • Specialty Clinics
  • Academic and Research Centers
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Liquid Biopsy Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Liquid Biopsy Market Snippet by Sample Type
    • 2.1.2. Liquid Biopsy Market Snippet by Biomarker
    • 2.1.3. Liquid Biopsy Market Snippet by Technology
    • 2.1.4. Liquid Biopsy Market Snippet by Product
    • 2.1.5. Liquid Biopsy Market Snippet by Clinical Application
    • 2.1.6. Liquid Biopsy Market Snippet by Application
    • 2.1.7. Liquid Biopsy Market Snippet by End-User
    • 2.1.8. Liquid Biopsy Market Snippet by Country
    • 2.1.9. Liquid Biopsy Market Snippet by Region
  • 2.2. Competitive Insights

3. Liquid Biopsy Key Market Trends

  • 3.1. Liquid Biopsy Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Liquid Biopsy Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Liquid Biopsy Market Opportunities
  • 3.4. Liquid Biopsy Market Future Trends

4. Liquid Biopsy Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Liquid Biopsy Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Liquid Biopsy Market Landscape

  • 6.1. Liquid Biopsy Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Liquid Biopsy Market - By Sample Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Sample Type, 2024 & 2032 (%)
    • 7.1.2. Blood Sample
    • 7.1.3. Others

8. Liquid Biopsy Market - By Biomarker

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Biomarker, 2024 & 2032 (%)
    • 8.1.2. Circulating Tumor Cells (CTCs)
    • 8.1.3. Circulating Tumor DNA (ctDNA)
    • 8.1.4. Extracellular Vehicles (EVs)
    • 8.1.5. Others

9. Liquid Biopsy Market - By Technology

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
    • 9.1.2. Multi-gene-parallel Analysis (NGS)
    • 9.1.3. Single Gene Analysis (PCR Microarrays)

10. Liquid Biopsy Market - By Product

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Product, 2024 & 2032 (%)
    • 10.1.2. Instruments
    • 10.1.3. Consumables Kits and Reagents
    • 10.1.4. Software and Services

11. Liquid Biopsy Market - By Clinical Application

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Clinical Application, 2024 & 2032 (%)
    • 11.1.2. Therapy Selection
    • 11.1.3. Treatment Monitoring
    • 11.1.4. Early Cancer Screening
    • 11.1.5. Recurrence Monitoring
    • 11.1.6. Others

12. Liquid Biopsy Market - By Application

  • 12.1. Overview
    • 12.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 12.1.2. Cancer
    • 12.1.3. Reproductive Health
    • 12.1.4. Lung Cancer
    • 12.1.5. Prostate Cancer
    • 12.1.6. Breast Cancer
    • 12.1.7. Colorectal Cancer
    • 12.1.8. Leukemia
    • 12.1.9. Gastrointestinal Cancer
    • 12.1.10. Others

13. Liquid Biopsy Market - By End-User

  • 13.1. Overview
    • 13.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
    • 13.1.2. Hospitals and Laboratories
    • 13.1.3. Specialty Clinics
    • 13.1.4. Academic and Research Centers
    • 13.1.5. Others

14. Liquid Biopsy Market- By Geography

  • 14.1. Introduction
    • 14.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 14.2. North America
    • 14.2.1. Overview
    • 14.2.2. Liquid Biopsy Key Manufacturers in North America
    • 14.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.2.4. North America Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.2.5. North America Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.2.6. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.2.7. North America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.2.8. North America Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.2.9. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.2.10. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.2.11. U.S.
      • 14.2.11.1. Overview
      • 14.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.11.3. U.S. Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.2.11.4. U.S. Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.2.11.5. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.2.11.6. U.S. Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.2.11.7. U.S. Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.2.11.8. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.2.11.9. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.2.12. Canada
      • 14.2.12.1. Overview
      • 14.2.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.12.3. Canada Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.2.12.4. Canada Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.2.12.5. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.2.12.6. Canada Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.2.12.7. Canada Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.2.12.8. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.2.12.9. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 14.3. Europe
    • 14.3.1. Overview
    • 14.3.2. Liquid Biopsy Key Manufacturers in Europe
    • 14.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.3.4. Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.3.5. Europe Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.3.6. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.3.7. Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.3.8. Europe Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.3.9. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.3.10. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.11. Germany
      • 14.3.11.1. Overview
      • 14.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.11.3. Germany Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.11.4. Germany Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.11.5. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.11.6. Germany Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.11.7. Germany Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.11.8. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.11.9. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.12. UK
      • 14.3.12.1. Overview
      • 14.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.12.3. UK Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.12.4. UK Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.12.5. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.12.6. UK Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.12.7. UK Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.12.8. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.12.9. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.13. France
      • 14.3.13.1. Overview
      • 14.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.13.3. France Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.13.4. France Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.13.5. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.13.6. France Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.13.7. France Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.13.8. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.13.9. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.14. Italy
      • 14.3.14.1. Overview
      • 14.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.14.3. Italy Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.14.4. Italy Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.14.5. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.14.6. Italy Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.14.7. Italy Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.14.8. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.14.9. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.15. Spain
      • 14.3.15.1. Overview
      • 14.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.15.3. Spain Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.15.4. Spain Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.15.5. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.15.6. Spain Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.15.7. Spain Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.15.8. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.15.9. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.16. The Netherlands
      • 14.3.16.1. Overview
      • 14.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.16.3. The Netherlands Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.16.4. The Netherlands Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.16.5. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.16.6. The Netherlands Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.16.7. The Netherlands Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.16.8. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.16.9. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.17. Sweden
      • 14.3.17.1. Overview
      • 14.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.17.3. Sweden Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.17.4. Sweden Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.17.5. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.17.6. Sweden Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.17.7. Sweden Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.17.8. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.17.9. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.18. Russia
      • 14.3.18.1. Overview
      • 14.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.18.3. Russia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.18.4. Russia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.18.5. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.18.6. Russia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.18.7. Russia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.18.8. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.18.9. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.19. Poland
      • 14.3.19.1. Overview
      • 14.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.19.3. Poland Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.19.4. Poland Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.19.5. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.19.6. Poland Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.19.7. Poland Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.19.8. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.19.9. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.20. Rest of Europe
      • 14.3.20.1. Overview
      • 14.3.20.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.20.3. Rest of the Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.20.4. Rest of the Europe Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.20.5. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.20.6. Rest of the Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.20.7. Rest of the Europe Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.20.8. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.20.9. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 14.4. Asia Pacific (APAC)
    • 14.4.1. Overview
    • 14.4.2. Liquid Biopsy Key Manufacturers in Asia Pacific
    • 14.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.4.4. APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.4.5. APAC Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.4.6. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.4.7. APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.4.8. APAC Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.4.9. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.4.10. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.11. China
      • 14.4.11.1. Overview
      • 14.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.11.3. China Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.11.4. China Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.11.5. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.11.6. China Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.11.7. China Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.11.8. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.11.9. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.12. India
      • 14.4.12.1. Overview
      • 14.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.12.3. India Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.12.4. India Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.12.5. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.12.6. India Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.12.7. India Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.12.8. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.12.9. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.13. Japan
      • 14.4.13.1. Overview
      • 14.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.13.3. Japan Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.13.4. Japan Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.13.5. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.13.6. Japan Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.13.7. Japan Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.13.8. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.13.9. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.14. South Korea
      • 14.4.14.1. Overview
      • 14.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.14.3. South Korea Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.14.4. South Korea Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.14.5. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.14.6. South Korea Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.14.7. South Korea Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.14.8. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.14.9. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.15. Australia
      • 14.4.15.1. Overview
      • 14.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.15.3. Australia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.15.4. Australia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.15.5. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.15.6. Australia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.15.7. Australia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.15.8. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.15.9. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.16. Indonesia
      • 14.4.16.1. Overview
      • 14.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.16.3. Indonesia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.16.4. Indonesia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.16.5. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.16.6. Indonesia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.16.7. Indonesia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.16.8. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.16.9. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.17. Thailand
      • 14.4.17.1. Overview
      • 14.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.17.3. Thailand Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.17.4. Thailand Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.17.5. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.17.6. Thailand Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.17.7. Thailand Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.17.8. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.17.9. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.18. Philippines
      • 14.4.18.1. Overview
      • 14.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.18.3. Philippines Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.18.4. Philippines Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.18.5. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.18.6. Philippines Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.18.7. Philippines Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.18.8. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.18.9. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.19. Rest of APAC
      • 14.4.19.1. Overview
      • 14.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.19.3. Rest of APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.19.4. Rest of APAC Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.19.5. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.19.6. Rest of APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.19.7. Rest of APAC Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.19.8. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.19.9. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 14.5. Latin America (LATAM)
    • 14.5.1. Overview
    • 14.5.2. Liquid Biopsy Key Manufacturers in Latin America
    • 14.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.5.4. LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.5.5. LATAM Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.5.6. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.5.7. LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.5.8. LATAM Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.5.9. LATAM Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.5.10. LATAM Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.11. Brazil
      • 14.5.11.1. Overview
      • 14.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.11.3. Brazil Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.11.4. Brazil Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.11.5. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.11.6. Brazil Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.11.7. Brazil Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.11.8. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.11.9. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.12. Mexico
      • 14.5.12.1. Overview
      • 14.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.12.3. Mexico Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.12.4. Mexico Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.12.5. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.12.6. Mexico Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.12.7. Mexico Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.12.8. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.12.9. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.13. Argentina
      • 14.5.13.1. Overview
      • 14.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.13.3. Argentina Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.13.4. Argentina Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.13.5. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.13.6. Argentina Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.13.7. Argentina Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.13.8. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.13.9. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.14. Colombia
      • 14.5.14.1. Overview
      • 14.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.14.3. Colombia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.14.4. Colombia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.14.5. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.14.6. Colombia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.14.7. Colombia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.14.8. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.14.9. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.15. Rest of LATAM
      • 14.5.15.1. Overview
      • 14.5.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.15.3. Rest of LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.15.4. Rest of LATAM Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.15.5. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.15.6. Rest of LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.15.7. Rest of LATAM Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.15.8. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.15.9. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 14.6. Middle East and Africa
    • 14.6.1. Overview
    • 14.6.2. Liquid Biopsy Key Manufacturers in Middle East and Africa
    • 14.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.6.4. Middle East and Africa Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.6.5. Middle East and Africa Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.6.6. Middle East and Africa Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.6.7. Middle East and Africa Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.6.8. Middle East and Africa Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.6.9. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.6.10. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.11. Saudi Arabia
      • 14.6.11.1. Overview
      • 14.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.11.3. Saudi Arabia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.11.4. Saudi Arabia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.11.5. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.11.6. Saudi Arabia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.11.7. Saudi Arabia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.11.8. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.11.9. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.12. United Arab Emirates
      • 14.6.12.1. Overview
      • 14.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.12.3. United Arab Emirates Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.12.4. United Arab Emirates Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.12.5. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.12.6. United Arab Emirates Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.12.7. United Arab Emirates Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.12.8. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.12.9. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.13. Israel
      • 14.6.13.1. Overview
      • 14.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.13.3. Israel Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.13.4. Israel Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.13.5. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.13.6. Israel Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.13.7. Israel Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.13.8. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.13.9. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.14. Turkey
      • 14.6.14.1. Overview
      • 14.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.14.3. Turkey Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.14.4. Turkey Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.14.5. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.14.6. Turkey Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.14.7. Turkey Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.14.8. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.14.9. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.15. Algeria
      • 14.6.15.1. Overview
      • 14.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.15.3. Algeria Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.15.4. Algeria Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.15.5. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.15.6. Algeria Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.15.7. Algeria Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.15.8. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.15.9. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.16. Egypt
      • 14.6.16.1. Overview
      • 14.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.16.3. Egypt Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.16.4. Egypt Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.16.5. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.16.6. Egypt Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.16.7. Egypt Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.16.8. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.16.9. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.17. Rest of MEA
      • 14.6.17.1. Overview
      • 14.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.17.3. Rest of MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.17.4. Rest of MEA Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.17.5. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.17.6. Rest of MEA Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.17.7. Rest of MEA Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.17.8. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.17.9. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

15. Key Vendor Analysis- Liquid Biopsy Industry

  • 15.1. Competitive Dashboard
    • 15.1.1. Competitive Benchmarking
    • 15.1.2. Competitive Positioning
  • 15.2. Company Profiles
    • 15.2.1. Guardant Health, Inc.
    • 15.2.2. Foundation Medicine, Inc. (Roche subsidiary)
    • 15.2.3. Illumina, Inc.
    • 15.2.4. GRAIL, Inc. (subsidiary of Illumina)
    • 15.2.5. Bio-Rad Laboratories, Inc.
    • 15.2.6. Exact Sciences Corporation
    • 15.2.7. Thermo Fisher Scientific Inc.
    • 15.2.8. Natera, Inc.
    • 15.2.9. Freenome Holdings, Inc.
    • 15.2.10. QIAGEN N.V.
    • 15.2.11. Lucence Diagnostics
    • 15.2.12. Inivata Ltd. (NeoGenomics subsidiary)
    • 15.2.13. Angle plc
    • 15.2.14. Sysmex Corporation
    • 15.2.15. Biocept, Inc.
    • 15.2.16. Oncocyte Corporation
    • 15.2.17. Personal Genome Diagnostics (PGDx)
    • 15.2.18. Chronix Biomedical
    • 15.2.19. Epic Sciences, Inc.
    • 15.2.20. Cynvenio Biosystems, Inc.
    • 15.2.21. Others

16. 360 Degree Analyst View

17. Appendix

  • 17.1. Research Methodology
  • 17.2. References
  • 17.3. Abbreviations
  • 17.4. Disclaimer
  • 17.5. Contact Us